Analyse morpho-structurelle de la dermatoporose par des méthodes non-invasives

La dermatoporose est définie comme un syndrome d'insuffisance cutanée chronique et de fragilité cutanée, résultant du vieillissement chronologique et d'autres facteurs tels que la photo-exposition, des facteurs génétiques, et l'utilisation de corticoïdes topiques ou systémiques. Cette entité a déjà été étudiée d'un point de vue histologique et ultrasonographique. L'objectif de ce travail était d'étudier la dermatoporose au moyen de la microscopie confocale in vivo, une technique d'imagerie cutanée non invasive, en comparant les données obtenues chez des patients et des volontaires sains. Nous sommes parvenus à définir des paramètres histométriques caractéristiques, qui apporteront une aide précieuse dans le diagnostic et le suivi thérapeutique de la dermatoporose

Successful treatment of scalp myxedema with injected hyaluronidase: a case report

Localized myxedema is an uncommon complication of Graves' disease. It is characterized by the accumulation of glycosaminoglycans, particularly hyaluronate. Here we describe the case of a 51-year-old female patient suffering from Graves' disease, who has presented for years a thickening of the scalp, consistent with myxedema, and successfully treated with repeated injections of hyaluronidase

Evaluation et prise en charge de l’hyperhidrose

Hyperhidrosis is excessive sweating beyond what is expected for thermoregulatory needs. Nearly 3 % of the population has hyperhidrosis. It may be primary or secondary to medications or general medical conditions, including diabetes mellitus, hyperthyroidism, Parkinson disease, etc. History taking and clinical examination are essential to differentiate primary from secondary origins. Blood tests and a consultation with a specialist (endocrinologist, neurologist) is sometimes necessary to establish the diagnosis. The management of secondary hyperhidrosis involves the treatment of the underlying cause. For primary hyperhidrosis, it depends on its severity and the sites affected. This article will review the treatments for primary hyperhidrosis

Pseudomalignancies in Children: Histological Clues, and Pitfalls to Be Avoided

The term "pseudomalignancy" covers a large, heterogenous group of diseases characterized by a benign cellular proliferation, hyperplasia, or infiltrate that resembles a true malignancy clinically or histologically. Here, we (i) provide a non-exhaustive review of several inflammatory skin diseases and benign skin proliferations that can mimic a malignant neoplasm in children, (ii) give pathologists some helpful clues to guide their diagnosis, and (iii) highlight pitfalls to be avoided. The observation of clinical-pathological correlations is often important in this situation and can sometimes be the only means (along with careful monitoring of the disease's clinical course) of reaching a firm diagnosis

Cutaneous Mucormycosis Resulting from Hematogenous Dissemination of Rhizomucor pusillus in an Immunocompromised Patient

Rhizomucor pusillus is an opportunistic fungus that causes infections (mucormycosis) in patients with a predisposing disease, such as diabetes mellitus and immunodeficiency. Classic manifestations are sinus, pulmonary, and skin infections. Skin lesions consist of tender, erythematous, indurated, and necrotic plaques. The diagnosis is made by identification of the organisms by histopathological analysis of the lesion, showing nonseptate fungal hyphae in the dermis and invasion of the vessel walls, or by means of cultures. Amphotericin B and surgery are the treatments of choice

Morphological analysis of dermatoporosis by in vivo reflectance confocal microscopy and ultrasonography

Dermatoporosis is defined as a chronic cutaneous fragility and insufficiency syndrome. It results from chronological aging, long-term and unprotected sun exposure, genetic factors, or the chronic use of topical and systemic corticosteroids. There is currently a lack of noninvasive tools for the evaluation and quantification of dermatoporosis

Perforating Fibrous Histiocytoma Mimicking Keratoacanthoma : A Case Report

A 31-year-old male presented with a firm, well-demarcated, erythematous, crateriform, and ulcerated nodule in the left lumbar region, which persisted for 3 months. Clinically, a keratoacanthoma was suspected. The histological analysis was consistent with perforating fibrous histiocytoma, a rare histopathologic variant of fibrous histiocytoma. To our knowledge, this is the third case reported in the literature

Injected Hyaluronidase Reduces the Volume of Exogenous Hyaluronate Fillers in Mice and Results in Clinical Improvement in a Patient with Pretibial Myxedema

Hyaluronidases are essential for the breakdown of hyaluronate (HA) in tissues and may be used to prevent the adverse effects of HA fillers

Injected Hyaluronidase Reduces the Volume of Exogenous Hyaluronate Fillers in Mice and Results in Clinical Improvement in a Patient with Pretibial Myxedema

Background: Hyaluronidases are essential for the breakdown of hyaluronate (HA) in tissues and may be used to prevent the adverse effects of HA fillers. Objectives: We explored the effect of hyaluronidase on exogenous and endogenous HA in vitro and in vivo. Materials and Methods: HA fillers were incubated with different concentrations of hyaluronidase and visualized by electrophoresis. HA fillers were injected in the skin of hairless mice, and 4 h later hyaluronidase was injected in the papules of exogenous HA. Hyaluronidase was injected in the nodule of pretibial myxedema of a male patient with Graves' disease. Skin sections of mice and of the patient were performed, and a skin ultrasound system was used to monitor the evolution of skin lesions. Results: Hyaluronidase showed a degrading effect on HA with increasing concentrations. Hyaluronidase injection significantly decreased the content of exogenous HA within 3 days. Intralesional injection of hyaluronidase resulted in dissolution of the nodule of pretibial myxedema with no recurrence during 3 months. Conclusion. These results show that the injection of hyaluronidase is capable of degrading exogenous HA in mouse skin and endogenous HA in human skin in vivo and may be a therapeutic option for skin diseases characterized by abnormal accumulation of HA